Evaluation of vamorolone CYP3A4 induction on midazolam (a sensitive CYP3A4 substrate) pharmacokinetics
SNT-I-VAM-025
Phase 1 other active
Quick answer
Evaluation of vamorolone CYP3A4 induction on midazolam (a sensitive CYP3A4 substrate) pharmacokinetics for Phase I study in healthy male volunteers. Intended indication: Duchenne muscular dystrophy and Becker muscular dystrophy is a Phase 1 program (other) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Phase I study in healthy male volunteers. Intended indication: Duchenne muscular dystrophy and Becker muscular dystrophy
- Phase
- Phase 1
- Modality
- other
- Status
- active